Antiviral Medications: Unravelling their Significance in Context to
COVID-19

Rishabh      Chalotra; Amanjot      Singh; Shivani      Chib; Swati      Gautam; Muhammed      Amanat; Kakul      Chaudhary; Manish      Kumar; Randhir      Singh

doi:10.2174/0126667975280977231224175043

Abstract

Viruses represent a significant health menace due to their rapid transmissibility and potential to cause worldwide pandemics, resulting in substantial loss of human life. Antiviral agents play a pivotal role in mitigating the impact of viral infections. Nonetheless, treating viral infections is a multifaceted process due to the inherent characteristics of viruses, such as their capacity to undergo mutations and rapid evolution. Consequently, the effectiveness of current antiviral therapies can be impeded. This review encompasses the diverse manners in which viruses, emphasizing COVID-19, affect the human body and elucidates the challenges encountered in formulating efficacious antiviral treatments. Moreover, the limitations of conventional antiviral therapies are underscored. Additionally, a comprehensive compendium of 41 antiviral drugs is presented, detailing their mechanisms of action and routes of administration. Subsequently, the discussion includes 9 drugs repurposed for treating COVID-19, delineating their primary use as well as any accompanying side effects. In conclusion, while antiviral drugs remain pivotal in the battle against viral infections, the obstacles associated with their development and usage warrant careful consideration. Ongoing research is imperative to devise more potent and less toxic antiviral interventions against COVID-19 infection.

Keywords: COVID-19, antiviral drugs, repurposing, nanotechnology, virus, JN.1.

Graphical Abstract

[1]
Gurunathan S, Qasim M, Choi Y, et al. Antiviral potential of nanoparticles-Can nanoparticles fight against coronaviruses? Nanomaterials  2020; 10(9): 1645.
 [http://dx.doi.org/10.3390/nano10091645] [PMID: 32825737]

[2]
Dube A. Nanomedicines for infectious diseases. Springer 2019.
 [http://dx.doi.org/10.1007/s11095-019-2603-x]

[3]
Qasim M, Lim DJ, Park H, Na D. Nanotechnology for diagnosis and treatment of infectious diseases. J Nanosci Nanotechnol  2014; 14(10): 7374-87.
 [http://dx.doi.org/10.1166/jnn.2014.9578] [PMID: 25942798]

[4]
Zhou P. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature  2020; 579(7798): 270-3.

[5]
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med  2020; 382(8): 727-33.
 [http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]

[6]
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet  2012; 380(9859): 2095-128.
 [http://dx.doi.org/10.1016/S0140-6736(12)61728-0] [PMID: 23245604]

[7]
Scott LJ, Perry CM. Delavirdine. Drugs  2000; 60(6): 1411-44.
 [http://dx.doi.org/10.2165/00003495-200060060-00013] [PMID: 11152019]

[8]
Vrouenraets SME, Wit FWNM, Tongeren J, Lange JMA. Efavirenz: A review. Expert Opin Pharmacother  2007; 8(6): 851-71.
 [http://dx.doi.org/10.1517/14656566.8.6.851] [PMID: 17425480]

[9]
Pai A, Pai GK, Muddukrishna B. Preparation, solid state characterization of etraverine Co-Crystals with improved solubility. Lat Am J Pharm  2017; 36(5): 972-9.

[10]
Mirochnick M, Clarke DF, Dorenbaum A. Nevirapine. Clin Pharmacokinet  2000; 39(4): 281-93.
 [http://dx.doi.org/10.2165/00003088-200039040-00004] [PMID: 11069214]

[11]
Goldsmith DR, Perry CM. Atazanavir. Drugs  2003; 63(16): 1679-93.
 [http://dx.doi.org/10.2165/00003495-200363160-00003] [PMID: 12904086]

[12]
Rizza SA. Boceprevir. Drugs Today  2011; 47(10): 743-51.

[13]
McKeage K, Perry CM, Keam SJ. Darunavir. Drugs  2009; 69(4): 477-503.
 [http://dx.doi.org/10.2165/00003495-200969040-00007] [PMID: 19323590]

[14]
Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clin Pharmacokinet  1998; 35(4): 275-91.
 [http://dx.doi.org/10.2165/00003088-199835040-00002] [PMID: 9812178]

[15]
González de Requena D, Blanco F, Garcia-Benayas T, Jiménez-Nácher I, González-Lahoz J, Soriano V. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS  2003; 17(9): 443-5.
 [http://dx.doi.org/10.1089/108729103322395465] [PMID: 14588081]

[16]
Plosker GL, Noble S. Indinavir. Drugs  1999; 58(6): 1165-203.
 [http://dx.doi.org/10.2165/00003495-199958060-00011] [PMID: 10651394]

[17]
Bardsley-Elliot A, Plosker GL. Nelfinavir. Drugs  2000; 59(3): 581-620.
 [http://dx.doi.org/10.2165/00003495-200059030-00014] [PMID: 10776836]

[18]
Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med  2011; 364(25): 2417-28.
 [http://dx.doi.org/10.1056/NEJMoa1013086] [PMID: 21696308]

[19]
King JR, Acosta EP. Tipranavir. Clin Pharmacokinet  2006; 45(7): 665-82.
 [http://dx.doi.org/10.2165/00003088-200645070-00003] [PMID: 16802849]

[20]
Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: Clinical pharmacology and pharmacokinetics. Clin Pharmacokinet  2004; 43(9): 595-612.
 [http://dx.doi.org/10.2165/00003088-200443090-00003] [PMID: 15217303]

[21]
Dando TM, Plosker GL. Adefovir dipivoxil. Drugs  2003; 63(20): 2215-34.
 [http://dx.doi.org/10.2165/00003495-200363200-00007] [PMID: 14498759]

[22]
Lea AP, Bryson HM. Cidofovir. Drugs  1996; 52(2): 225-30.
 [http://dx.doi.org/10.2165/00003495-199652020-00006] [PMID: 8841740]

[23]
Brocato RL, Hooper JW. Progress on the prevention and treatment of hantavirus disease. Viruses  2019; 11(7): 610.
 [http://dx.doi.org/10.3390/v11070610] [PMID: 31277410]

[24]
Taylor K, Fritz K, Parmar M. Lamivudine. StatPearls 2020.

[25]
Sungkanuparph S, Manosuth W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis  2007; 44(3): 447-52.
 [http://dx.doi.org/10.1086/510745] [PMID: 17205457]

[26]
Gao WY, Shirasaka T, Johns DG, Broder S, Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest  1993; 91(5): 2326-33.
 [http://dx.doi.org/10.1172/JCI116463] [PMID: 8387546]

[27]
Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother  1997; 41(4): 757-62.
 [http://dx.doi.org/10.1128/AAC.41.4.757] [PMID: 9087484]

[28]
Hodge RAV, Cheng YC. The mode of action of penciclovir. Antivir Chem Chemother  1993; 4(6) (Suppl.): 13-24.
 [http://dx.doi.org/10.1177/09563202930040S601]

[29]
Kausar S, Said Khan F, Ishaq Mujeeb URM, et al. A review: Mechanism of action of antiviral drugs. Int J Immunopathol Pharmacol  2021; 35: 20587384211002621.
 [http://dx.doi.org/10.1177/20587384211002621] [PMID: 33726557]

[30]
Meyers JD, Wade JC, Mitchell CD, et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med  1982; 73(1): 229-35.
 [http://dx.doi.org/10.1016/0002-9343(82)90097-3] [PMID: 7048914]

[31]
McGavin JK, Goa KL. Ganciclovir. Drugs  2001; 61(8): 1153-83.
 [http://dx.doi.org/10.2165/00003495-200161080-00016] [PMID: 11465876]

[32]
Seth AK, Misra A, Umrigar D. Topical liposomal gel of idoxuridine for the treatment of herpes simplex: Pharmaceutical and clinical implications. Pharm Dev Technol  2005; 9(3): 277-89.
 [http://dx.doi.org/10.1081/PDT-200031432] [PMID: 15458233]

[33]
Robinson DM, Scott LJ, Plosker GL. Entecavir. Drugs  2006; 66(12): 1605-22.
 [http://dx.doi.org/10.2165/00003495-200666120-00009] [PMID: 16956310]

[34]
Le P, Rothberg M. Herpes zoster infection. BMJ  2019; 364: k5095.
 [http://dx.doi.org/10.1136/bmj.k5095] [PMID: 30630827]

[35]
Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Trifluridine. Drugs  1982; 23(5): 329-53.
 [http://dx.doi.org/10.2165/00003495-198223050-00001] [PMID: 6284470]

[36]
Acosta EP, Fletcher CV. Valacyclovir. Ann Pharmacother  1997; 31(2): 185-91.
 [http://dx.doi.org/10.1177/106002809703100211] [PMID: 9034421]

[37]
Wilde MI, Langtry HD. Zidovudine. Drugs  1993; 46(3): 515-78.
 [http://dx.doi.org/10.2165/00003495-199346030-00010] [PMID: 7693435]

[38]
Dunn CJ, Goa KL. Zanamivir. Drugs  1999; 58(4): 761-84.
 [http://dx.doi.org/10.2165/00003495-199958040-00016] [PMID: 10551442]

[39]
McClellan K, Perry CM. Oseltamivir. Drugs  2001; 61(2): 263-83.
 [http://dx.doi.org/10.2165/00003495-200161020-00011] [PMID: 11270942]

[40]
Geary RS, Henry SP, Grillone LR. Fomivirsen. Clin Pharmacokinet  2002; 41(4): 255-60.
 [http://dx.doi.org/10.2165/00003088-200241040-00002] [PMID: 11978144]

[41]
Bergmann M, Beer R, Kofler M, Helbok R, Pfausler B, Schmutzhard E. Acyclovir resistance in herpes simplex virus type I encephalitis: A case report. J Neurovirol  2017; 23(2): 335-7.
 [http://dx.doi.org/10.1007/s13365-016-0489-5] [PMID: 27787806]

[42]
Tembhurne SJ, Nirwan KR, Lade UB. A comperhensive on anti viral drug used in the skin infection 2021.

[43]
Croxtall JD, Lyseng-Williamson KA, Perry CM. Raltegravir. Drugs  2008; 68(1): 131-8.
 [http://dx.doi.org/10.2165/00003495-200868010-00009] [PMID: 18081377]

[44]
Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet  2011; 50(4): 229-44.
 [http://dx.doi.org/10.2165/11584570-000000000-00000] [PMID: 21348537]

[45]
Holmes EC, Hurt AC, Dobbie Z, Clinch B, Oxford JS, Piedra PA. Understanding the impact of resistance to influenza antivirals. Clin Microbiol Rev  2021; 34(2): e00224-20.
 [http://dx.doi.org/10.1128/CMR.00224-20] [PMID: 33568554]

[46]
Gavrilova NS, Gavrilov LA. Patterns of mortality during pandemic: An example of Spanish flu pandemic of 1918. Popul Econ  2020; 4(2): 56-64.
 [http://dx.doi.org/10.3897/popecon.4.e53492]

[47]
Chalotra R, Gupta T, Chib S, Amanat M, Kumar P, Singh R. Treatment of diabetic complications: Do flavonoids holds the keys? Crit Rev Food Sci Nutr  2023; 1-22.
 [http://dx.doi.org/10.1080/10408398.2023.2232868] [PMID: 37435788]

[48]
Pardo J, Shukla AM, Chamarthi G, Gupte A. The journey of remdesivir: From Ebola to COVID-19. Drugs Context  2020; 9: 1-9.
 [http://dx.doi.org/10.7573/dic.2020-4-14] [PMID: 32547625]

[49]
Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med  2021; 384(8): 693-704.
 [http://dx.doi.org/10.1056/NEJMoa2021436] [PMID: 32678530]

[50]
Akhtar J, Shukla D. Viral entry mechanisms: Cellular and viral mediators of herpes simplex virus entry. FEBS J  2009; 276(24): 7228-36.
 [http://dx.doi.org/10.1111/j.1742-4658.2009.07402.x] [PMID: 19878306]

[51]
Milovanovic M. Nanoparticles in antiviral therapy.  In: Antimicrobial nanoarchitectonics.  Elsevier 2017; pp. 383-410.
 [http://dx.doi.org/10.1016/B978-0-323-52733-0.00014-8]

[52]
Institute NHGR. National Human Genome Research Institute, genome.gov. Online 2022.

[53]
Filip R, Gheorghita Puscaselu R, Anchidin-Norocel L, Dimian M, Savage WK. Global challenges to public health care systems during the COVID-19 pandemic: A review of pandemic measures and problems. J Pers Med  2022; 12(8): 1295.
 [http://dx.doi.org/10.3390/jpm12081295] [PMID: 36013244]

[54]
Chaudhary R, Chalotra R, Singh R. Sources and occurrence of pharmaceuticals residue in the aquatic environment.  In: Pharmaceuticals in Aquatic Environments.  13-29.
 [http://dx.doi.org/10.1201/9781003361091-2]

[55]
Organization WH. Naming the coronavirus disease (COVID-19) and the virus that causes it. Brazi J Implantol Health Sci  2020; 2(3)

[56]
Tyrrell DAJ, Bynoe ML. Cultivation of viruses from a high proportion of patients with colds. Lancet  1966; 287(7428): 76-7.
 [http://dx.doi.org/10.1016/S0140-6736(66)92364-6] [PMID: 4158999]

[57]
Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health  2020; 25(3): 278-80.
 [http://dx.doi.org/10.1111/tmi.13383] [PMID: 32052514]

[58]
WHO Tracking SARS-CoV-2 variants.  2022. Available from: https://who.int/activities/tracking-SARS-CoV-2-variants

[59]
Looi MK. Covid-19: WHO adds JN. 1 as new variant of interest 

[60]
Ramandeep Kaur RC. Research and development in pharmaceutical science. Bhumi Publishing 2021.

[61]
Chalotra R, Dhanawat M, Maivagna CH, Gupta S. Traditional drugs originating from selected medicinal plants: An intervention for anaemia. Curr Tradit Med  2023; 9(6): e050123212400.
 [http://dx.doi.org/10.2174/2215083809666230105161143]

[62]
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents  2020; 56(1): 105949.
 [http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205204]

[63]
Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med  2013; 368(18): 1704-12.
 [http://dx.doi.org/10.1056/NEJMoa1300799] [PMID: 23635050]

[64]
Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med  2020; 383(6): 517-25.
 [http://dx.doi.org/10.1056/NEJMoa2016638] [PMID: 32492293]

[65]
Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet  1996; 31(4): 257-74.
 [http://dx.doi.org/10.2165/00003088-199631040-00003] [PMID: 8896943]

[66]
Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis  2006; 6(2): 67-9.
 [http://dx.doi.org/10.1016/S1473-3099(06)70361-9] [PMID: 16439323]

[67]
Stein M, Bell MJ, Ang L-C. Hydroxychloroquine neuromyotoxicity. J Rheumatol  2000; 27(12): 2927-31.
 [PMID: 11128688]

[68]
Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Postgrad Med J  2020; 96(1139): 550-5.
 [http://dx.doi.org/10.1136/postgradmedj-2020-137785] [PMID: 32295814]

[69]
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med  2020; 382(19): 1787-99.
 [http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]

[70]
Cvetkovic RS, Goa KL. Lopinavir/Ritonavir. Drugs  2003; 63(8): 769-802.
 [http://dx.doi.org/10.2165/00003495-200363080-00004] [PMID: 12662125]

[71]
Şi̇mşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci  2020; 50(SI-1): 611-9.
 [http://dx.doi.org/10.3906/sag-2004-145] [PMID: 32293834]

[72]
Fox LM, Saravolatz LD. Nitazoxanide: A new thiazolide antiparasitic agent. Clin Infect Dis  2005; 40(8): 1173-80.
 [http://dx.doi.org/10.1086/428839] [PMID: 15791519]

[73]
Abaza H, El-Zayadi AR, Kabil SM, Rizk H. Nitazoxanide in the treatment of patients with intestinal protozoan and helminthic infections: A report on 546 patients in egypt. Curr Ther Res Clin Exp  1998; 59(2): 116-21.
 [http://dx.doi.org/10.1016/S0011-393X(98)85006-6]

[74]
Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health  2016; 9(3): 227-30.
 [http://dx.doi.org/10.1016/j.jiph.2016.04.001] [PMID: 27095301]

[75]
Al-kuraishy HM, Batiha GES, Faidah H, Al-Gareeb AI, Saad HM, Simal-Gandara J. Pirfenidone and post-COVID-19 pulmonary fibrosis: Invoked again for realistic goals. Inflammopharmacology  2022; 30(6): 2017-26.
 [http://dx.doi.org/10.1007/s10787-022-01027-6] [PMID: 36044102]

[76]
Carter NJ. Pirfenidone. Drugs  2011; 71(13): 1721-32.
 [http://dx.doi.org/10.2165/11207710-000000000-00000] [PMID: 21902295]

[77]
Hanta I, Cilli A, Sevinc C. The effectiveness, safety, and tolerability of Pirfenidone in idiopathic pulmonary fibrosis: A retrospective study. Adv Ther  2019; 36(5): 1126-31.
 [http://dx.doi.org/10.1007/s12325-019-00928-3] [PMID: 30900199]

[78]
Mohammad Zadeh N, Mashinchi Asl NS, Forouharnejad K, et al. Mechanism and adverse effects of COVID-19 drugs: A basic review. Int J Physiol Pathophysiol Pharmacol  2021; 13(4): 102-9.
 [PMID: 34540130]

[79]
Abbass S, Kamal E, Salama M, et al. Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. J Med Virol  2021; 93(12): 6750-9.
 [http://dx.doi.org/10.1002/jmv.27264] [PMID: 34379337]

[80]
Pol S, Bourliere M, Lucier S, et al. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J Hepatol  2017; 66(1): 39-47.
 [http://dx.doi.org/10.1016/j.jhep.2016.08.021] [PMID: 27622858]

[81]
Simmons B, Wentzel H, Mobarak S, et al. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. J Antimicrob Chemother  2021; 76(2): 286-91.
 [http://dx.doi.org/10.1093/jac/dkaa418] [PMID: 33063117]

[82]
Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet  2021; 397(10285): 1637-45.
 [http://dx.doi.org/10.1016/S0140-6736(21)00676-0] [PMID: 33933206]

[83]
Oldfield V, Dhillon S, Plosker GL. Tocilizumab. Drugs  2009; 69(5): 609-32.
 [http://dx.doi.org/10.2165/00003495-200969050-00007] [PMID: 19368420]

[84]
Amanat M. Zingiber roseum Roscoe(Zingiberaceae): Current and future perspective 2023; 100258.

[85]
DeSimone DC. COVID-19 variants: What’s the concern?.  2022. Available from: https://www.mayoclinic.org/diseases-conditions/coronavirus/expert-answers/covid-variant/faq-20505779

[86]
Oshikoya KA. Ogunleye, Lawal, Senbanjo S, Oreagba. Clinically significant interactions between antiretroviral and co-prescribed drugs for HIV-infected children: Profiling and comparison of two drug databases. Ther Clin Risk Manag  2013; 9: 215-21.
 [http://dx.doi.org/10.2147/TCRM.S44205] [PMID: 23700368]

[87]
Chakravarty M, Vora A. Nanotechnology-based antiviral therapeutics. Drug Deliv Transl Res  2021; 11(3): 748-87.
 [http://dx.doi.org/10.1007/s13346-020-00818-0] [PMID: 32748035]

[88]
Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol  2009; 86(3): 215-23.
 [http://dx.doi.org/10.1016/j.yexmp.2008.12.004] [PMID: 19186176]

[89]
Vyas SP, Subhedar R, Jain S. Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. J Pharm Pharmacol  2010; 58(3): 321-6.
 [http://dx.doi.org/10.1211/jpp.58.3.0005] [PMID: 16536898]

[90]
De Clercq E. Antivirals: Past, present and future. Biochem Pharmacol  2013; 85(6): 727-44.
 [http://dx.doi.org/10.1016/j.bcp.2012.12.011] [PMID: 23270991]

[91]
Adalja A, Inglesby T. Broad-spectrum antiviral agents: A crucial pandemic tool. Expert Rev Anti Infect Ther  2019; 17(7): 467-70.
 [http://dx.doi.org/10.1080/14787210.2019.1635009] [PMID: 31216912]

[92]
Chauhan S. Current approaches in healing of wounds in diabetes and diabetic foot ulcers. Curr Bioact Compd  2023; 19(3): 104-21.

[93]
Emerich DF, Thanos CG. Nanotechnology and medicine. Expert Opin Biol Ther  2003; 3(4): 655-63.
 [http://dx.doi.org/10.1517/14712598.3.4.655] [PMID: 12831370]

[94]
Thangadurai D, Islam S, Adetunji CO. Viral and Antiviral Nanomaterials: Synthesis, Properties, Characterization, and Application. CRC Press 2022.

[95]
Rishabh Chalotra MD. Samrat chauhan, somdutt mujwar, sumeet gupta, evaluation of iris kashmiriana baker plant extracts against nociception and rheumatoid arthritis in experimental rats: A concept proof by in silico model. J Ethnopharmacol 2023.

[96]
Chalotra R, Dhanawat M, Maqbool M, Lamba N, Bibi A, Gupta S. Phytochemistry and pharmacology of iris kashmiriana. Pharmacognosy Res  2022; 14(4): 350-5.
 [http://dx.doi.org/10.5530/pres.14.4.52]

[97]
Xu K, Liang ZC, Ding X, et al. Nanomaterials in the prevention, diagnosis, and treatment of mycobacterium tuberculosis infections. Adv Healthc Mater  2018; 7(1): 1700509.
 [http://dx.doi.org/10.1002/adhm.201700509] [PMID: 28941042]

[98]
Amini Pouya M, Afshani SM, Maghsoudi AS, Hassani S, Mirnia K. Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection. Daru  2020; 28(2): 745-64.
 [http://dx.doi.org/10.1007/s40199-020-00359-4] [PMID: 32734518]

Rights & Permissions Print Cite

Article Metrics

17

2

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0126667975280977231224175043	Print ISSN 2666-7967
Publisher Name Bentham Science Publisher	Online ISSN 2666-7975

Coronaviruses

Antiviral Medications: Unravelling their Significance in Context to COVID-19

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles